Summit PLC
The second recipient of the charity's funding was an Oxford based drug development company, Summit PLC, who is developing a utrophin drug called SMT C1100 that could potentially slow or even stop progression of the disease in all DMD boys. The funding (£100,000) will support development of bio-markers that will help measure the effectiveness of this drug as it now starts to be tested in patient clinical trials.
"The DMD community is playing a key role in the development of promising therapies for DMD such as our drug SMT C1100," commented Glyn Edwards, Chief Executive Officer of Summit. "Summit is delighted to receive this funding from Joining Jack which will help advance a vital part of our research towards generating potential life-changing treatments for this devastating disease."
Our Projects
- Solid GT
- The Newcastle Plan
- Lectureship to develop clinical trial agenda
- Reveragen
- Tamoxifen Trial
- Summit PLC
- University of Geneva Combination and Repurposing Study
- Soy Products
- Halo Therapeutics
- Alder Hey Heart Protection Study
- The Duchenne Forum
- Cannabidiol (CBD)
- A Combination Study
- DMD Programme Co-ordinator
- Elastase Inhibitors
- Understanding the causes of heart disease in DMD
- Evox Therapeutics
- Tamoxifen Open Label Extension Study
- Adult Neuromuscular Complex Care Centre
How You Can Help
There are many ways that you can help us to beat DMD.
You could simply donate online:
Find out more ways to donate to Joining Jack.
Take a look at this section to find out further ways that you can help us beat DMD.
